Wegovy Across Menopause: What the May 2026 Data Means for Women in Their 40s and 50s

Perimenopause is the period in a woman's life — typically her 40s — when ovarian function starts to decline, estrogen levels fluctuate, and the metabolic, sleep, mood, and body-composition changes that everyone associates with 'menopause' are actually happening. Weight gain during this window is common: average gain across the perimenopausal transition is 1.5-2 kg per year, concentrated in visceral adipose tissue. The 'menopause middle' is not a myth.

The question most women starting a GLP-1 during this period have asked their prescribers — and gotten partial answers to — is whether the drug works as well during hormonal flux. Reasonable hypotheses pointed both ways. On one hand, declining estrogen reduces insulin sensitivity and shifts fat distribution toward the visceral depot; a GLP-1 might work especially well against the specific adiposity pattern of perimenopause. On the other hand, hormonal volatility might disrupt appetite-regulating circuits in ways that blunt the drug's effect.

The ECO 2026 STEP UP post-hoc analysis presented May 12 finally answers the question with real numbers. The answer is unambiguous: it works the same.

Novo Nordisk's STEP UP post-hoc analysis stratified Wegovy 7.2 mg outcomes by reproductive life stage. The results at week 72:

Premenopausal women: 22.6% mean body-weight loss. 41.4% reached ≥25% loss.

Perimenopausal women: 19.7% mean body-weight loss.

Postmenopausal women: 19.8% mean body-weight loss.

The three numbers are statistically indistinguishable — the trial wasn't designed to detect a 1-2 percentage-point difference between subgroups, and the confidence intervals overlap. What the data does show, clearly, is that Wegovy 7.2 mg produces large and clinically meaningful weight loss across all three life stages.

Waist circumference reductions tracked the body-weight numbers: 17.5 cm in premenopausal, 15.6 cm in perimenopausal, 15.3 cm in postmenopausal women. Slightly larger absolute reductions in the younger group, but proportionally similar to baseline waist measurements. The drug doesn't seem to work less hard against perimenopausal or postmenopausal adiposity. It just works against bodies that started with somewhat different baseline body composition.

For a 47-year-old woman starting Wegovy who's also navigating hot flashes, sleep disruption, and unpredictable cycles, the practical takeaway is that the drug data matches the under-40 data. Plan for 18-22% weight loss at the 7.2 mg dose. Adjust expectations downward by a percentage point or two if there are individual-level reasons to (low protein intake, sedentary baseline, sleep disruption from night sweats). The hormone-driven gain during perimenopause is reversible with appropriate pharmacologic and lifestyle intervention.

Alongside the STEP UP trial post-hoc, Novo Nordisk presented a real-world analysis of 34,000+ women drawn from claims data. Women taking Wegovy showed:

A 42-45% lower risk of migraine starting six months after initiating treatment, compared with women on menopausal hormone therapy alone.

A 25% lower risk of depression, also starting six months in.

These aren't randomized-controlled-trial results. They're observational signals from a large claims database, with all the confounders that come with that kind of data — selection bias on who gets a GLP-1 prescription, differential follow-up, prescriber and payer effects, and the fact that women who lose 15-20% of body weight tend to feel better in lots of ways that are difficult to disentangle.

The migraine signal is biologically plausible. Migraine prevalence in women rises sharply around menopause, and CGRP-pathway involvement (the basis for the migraine biologics like Ajovy, Emgality, Aimovig) overlaps with metabolic-disease pathways. There's a reasonable mechanistic story for why GLP-1s might modulate migraine risk independent of weight loss — vagal afferent signaling, central anti-inflammatory effects, glucose stability. But it's a story, not a confirmed mechanism.

The depression signal is harder to interpret. Weight loss itself improves depression scores in observational studies; the 2026 Lancet Psychiatry Karolinska cohort study on semaglutide in people with depression and anxiety showed lower psychiatric hospitalizations in the GLP-1 arm; the social-stigma research (Rice University, May 5, 2026) suggests some patients feel worse about themselves on the drug, not better. The 25% real-world reduction is probably a real effect, but the magnitude attributable to the drug specifically — versus weight loss, versus selection, versus shared cardiovascular and metabolic improvement — is unclear. Treat it as encouraging directional evidence, not a clinical claim.

On the same May 12 ECO 2026 schedule, Novo presented a SELECT post-hoc stratified by reproductive life stage. SELECT was the landmark cardiovascular outcomes trial showing 20% reduction in major adverse cardiovascular events (MACE) for adults with established cardiovascular disease and obesity on semaglutide. The subgroup analysis broke that 20% into life-stage strata:

Perimenopausal women with obesity and heart disease: 42% lower MACE risk on semaglutide vs placebo.

Postmenopausal women with obesity and heart disease: 13% lower MACE risk vs placebo.

That gap is striking. The perimenopausal benefit is more than double the population-average SELECT result. The postmenopausal benefit is meaningfully smaller than the average.

A reasonable interpretation: perimenopausal women in SELECT had cardiovascular disease that was more responsive to metabolic intervention than postmenopausal women, possibly because their underlying CV risk was driven more by metabolic factors (insulin resistance, central adiposity, dyslipidemia) and less by long-duration structural disease (atherosclerotic plaque burden, LV remodeling). Or the perimenopausal cohort was younger, healthier on average, and had more room for benefit. Or there's a specific hormonal-metabolic interaction at play. The trial wasn't powered to pin down which.

For a perimenopausal woman with known cardiovascular disease — say, a 49-year-old with a previous MI or stent placement — the SELECT subgroup data is the strongest evidence-based argument for starting a GLP-1 that exists. The cardiovascular benefit is large, the absolute risk reduction is meaningful, and it sits on top of the weight-loss and metabolic benefits. For a postmenopausal woman with longer-duration CVD, the cardiovascular case is still positive but smaller. Either way, the drug is doing real work; the magnitude varies.

One thing the ECO data doesn't address directly: does Wegovy meaningfully change hot flashes, night sweats, and other vasomotor symptoms of perimenopause? The answer is 'probably yes but we don't have great trial evidence.'

Mechanistically, the connection runs through visceral adiposity and inflammation. Vasomotor symptom severity correlates with central adiposity and inflammatory marker levels; reducing both tends to reduce symptom frequency. A 15-20% weight loss with corresponding waist-circumference reduction would be expected to improve vasomotor symptoms in many women. But Wegovy isn't approved for vasomotor symptoms, no Phase 3 trial has been designed specifically around them, and the existing literature is mostly observational.

The May 2026 ECO data has another interesting wrinkle: Wegovy is being used by some women alongside menopausal hormone therapy (MHT). The 34,000-woman cohort compared Wegovy-using women to women on MHT alone, finding migraine and depression benefits — but there's no head-to-head data on whether combining Wegovy with MHT produces additive metabolic benefits or whether women should choose one or the other. Most prescribers manage them in parallel; some endocrinologists prefer to optimize one before adding the other. The clinical practice hasn't yet converged on a standard sequence.

A balanced picture also requires acknowledging where the perimenopausal cohort has specific exposures the trial-wide data doesn't fully cover.

Bone density loss accelerates around menopause, and rapid weight loss is independently associated with bone-density reduction. A perimenopausal woman losing 15-20% of body weight on a GLP-1 may experience clinically meaningful bone-density reduction that compounds the bone effects of declining estrogen. The under-50 SURMOUNT and STEP data doesn't break this out cleanly. Reasonable practical step: baseline DEXA before starting if you're 45+ with osteopenia or osteoporosis risk factors (low BMI, family history, smoking history, steroid use), recheck after 18-24 months of treatment.

Muscle preservation matters more in this cohort than in younger women. Estrogen decline reduces muscle-building response to resistance training; combined with caloric restriction from the GLP-1, the risk of sarcopenic obesity (high body fat with low muscle mass) is real. The 1.2-1.6 g/kg protein target applies, ideally distributed across 3-4 meals; resistance training 2-3 times a week becomes more important than for younger women.

Gastrointestinal tolerability may be worse during perimenopause for some women. Hormonal flux contributes to GI motility changes; layering a GLP-1's slowed-gastric-emptying effect on top of perimenopausal GI symptoms (bloating, constipation, reflux) can make first-month tolerability harder. The titration playbook — slow up-titration, electrolyte support, deliberate hydration — applies more strongly here. Some women report that GLP-1 nausea overlaps unpredictably with perimenopause-related nausea; tracking both helps disentangle them.

None of these are reasons not to start the drug if it's clinically indicated. They're reasons to start with eyes open and build the monitoring infrastructure that catches problems early.

Pulled into a working summary:

The drug works during perimenopause and postmenopause approximately as well as it works premenopausally. Plan for 18-22% mean weight loss at higher doses (Wegovy 7.2 mg, equivalent tirzepatide doses). Adjust expectations slightly downward, not dramatically.

The cardiovascular benefit appears to be larger in perimenopausal women with established cardiovascular disease than the population average suggests. For a 45-55-year-old with a coronary calcium score, an MI history, or stent placement, the GLP-1 case is among the strongest in the data.

The migraine and depression real-world signals are encouraging but observational. Don't start the drug specifically for migraine or depression. If those symptoms improve as a side benefit, that's worth tracking — and worth telling your prescriber about, because the larger trials Novo will likely run in this space will need real-world signals to design well.

Monitor bone density and lean mass deliberately. Baseline DEXA at 45+, recheck at 18-24 months. Protein target 1.2-1.6 g/kg/day. Resistance training 2-3x/week. Don't skip these — they're more important here than for younger cohorts.

MHT alongside a GLP-1 isn't contraindicated and most prescribers manage them in parallel. There's no head-to-head evidence on optimal sequencing yet. If hot flashes are a primary symptom, optimizing MHT first may be reasonable; if metabolic disease is the primary indication, starting the GLP-1 first usually is. Talk to your prescriber about both.

Most importantly: the era when 'GLP-1s in women' was a research gap is over. The data is now better for perimenopausal and postmenopausal women than for many other prescribing decisions in primary care.